November 1, 1994Journal of Bone and Joint SurgeryOpen Access

Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety.

View Full Paper

Ask AI

Bookmark

Why the study?

Does enoxaparin prevent deep venous thrombosis compared to unfractionated heparin in patients after elective hip replacement?

Population

Patients undergoing elective hip replacement

Comparison

Enoxaparin (low-molecular-weight heparin) vs Unfractionated heparin

Design

RCT, randomized, parallel-group, open-label

Authors

PLPaul E. LevinAlbert Einstein College of Medicine

Discussion

Member takes

Implication

Twice-daily enoxaparin outperforms unfractionated heparin for DVT prevention after elective hip replacement; reinforces LMWH preference in orthopedic VTE prophylaxis.

Structured PICO

Does enoxaparin prevent deep venous thrombosis compared to unfractionated heparin in patients after elective hip replacement?

Population

Patients undergoing elective hip replacement

Intervention

Enoxaparin (low-molecular-weight heparin)

Comparator

Unfractionated heparin

Outcome

Prevention of deep venous thrombosis and safetyhard clinical

Cite This Study

Paul E. Levin (1994) studied this question.

synapsesocial.com/papers/6a8570d38e43bc0304d0bcc6 https://doi.org/10.2106/00004623-199411000-00021

View Full Paper

Ask AI

Bookmark

Implication

Twice-daily enoxaparin outperforms unfractionated heparin for DVT prevention after elective hip replacement; reinforces LMWH preference in orthopedic VTE prophylaxis.